Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabies virus strain pm-1503-3m
- Development stage
- Approved
- Lead developer
- The Wistar Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
Rabies virus strain PM‑1503‑3M is an inactivated (beta-propiolactone-inactivated) rabies virus derived from the Pitman Moore (Wistar) lineage, used as the active component in several human diploid cell culture-based vaccines for pre-exposure and post-exposure prophylaxis against rabies. The vaccine is produced by propagating the virus in human diploid cells (such as MRC‑5 or WI‑38), followed by concentration and chemical inactivation. It induces a robust immune response with high titers of neutralizing antibodies, providing effective protection against rabies infection when administered according to recommended schedules. This strain was originally developed at The Wistar Institute and has been widely adopted globally for its safety and efficacy profile[2][4][5][6].
- Brand names
- Imovax RabiesVerorab
- Other names
- rabies virus inactivated antigen Brabies virus strain pm-hdcs, 1503–3m
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on rabies virus strain pm-1503-3m.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabies virus strain pm-1503-3m.